Steven Valiquette
Stock Analyst at Mizuho
(3.23)
# 986
Out of 5,182 analysts
130
Total ratings
49.25%
Success rate
2.48%
Average return
Main Sectors:
Stocks Rated by Steven Valiquette
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HSIC Henry Schein | Maintains: Neutral | $88 → $82 | $69.63 | +17.77% | 8 | May 6, 2026 | |
| XRAY DENTSPLY SIRONA | Maintains: Neutral | $16 → $14 | $10.83 | +29.27% | 10 | May 6, 2026 | |
| PHR Phreesia | Maintains: Outperform | $22 → $19 | $9.89 | +92.11% | 3 | Mar 24, 2026 | |
| LFMD LifeMD | Upgrades: Outperform | $6 → $8 | $4.64 | +72.41% | 3 | Mar 16, 2026 | |
| GDRX GoodRx Holdings | Maintains: Neutral | $4 → $3 | $2.79 | +7.53% | 2 | Feb 27, 2026 | |
| DOCS Doximity | Maintains: Neutral | $45 → $34 | $25.52 | +33.23% | 4 | Feb 10, 2026 | |
| NVST Envista Holdings | Maintains: Neutral | $24 → $27 | $24.30 | +11.11% | 4 | Feb 10, 2026 | |
| CAH Cardinal Health | Maintains: Outperform | $222 → $235 | $188.60 | +24.60% | 8 | Feb 6, 2026 | |
| MCK McKesson | Maintains: Neutral | $880 → $885 | $765.23 | +15.65% | 5 | Feb 5, 2026 | |
| ALGN Align Technology | Maintains: Outperform | $170 → $200 | $165.53 | +20.82% | 13 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $85 → $100 | $72.29 | +38.34% | 3 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $40.19 | +19.43% | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $340 → $380 | $264.11 | +43.88% | 3 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $50 | $21.07 | +137.30% | 2 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $295 → $325 | $165.90 | +95.91% | 4 | Aug 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $10 | $7.04 | +42.15% | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $126 | $83.65 | +50.63% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $5.20 | -3.75% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $142 | $170.90 | -16.91% | 10 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 | $87.35 | -37.03% | 6 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $92 | $216.51 | -57.51% | 10 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $565 | $373.93 | +51.10% | 5 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $100 | $89.63 | +11.58% | 1 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $380 → $400 | $184.23 | +117.12% | 4 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $107 | $54.72 | +95.54% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $22 → $17 | $40.98 | -58.52% | 3 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $5 → $12 | $13.44 | -10.68% | 1 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $96 | $107.34 | -10.56% | 3 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $105 → $120 | $188.70 | -36.41% | 6 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $117 → $127 | $434.27 | -70.76% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $327 → $358 | $257.60 | +38.98% | 3 | Dec 6, 2019 |
Henry Schein
May 6, 2026
Maintains: Neutral
Price Target: $88 → $82
Current: $69.63
Upside: +17.77%
DENTSPLY SIRONA
May 6, 2026
Maintains: Neutral
Price Target: $16 → $14
Current: $10.83
Upside: +29.27%
Phreesia
Mar 24, 2026
Maintains: Outperform
Price Target: $22 → $19
Current: $9.89
Upside: +92.11%
LifeMD
Mar 16, 2026
Upgrades: Outperform
Price Target: $6 → $8
Current: $4.64
Upside: +72.41%
GoodRx Holdings
Feb 27, 2026
Maintains: Neutral
Price Target: $4 → $3
Current: $2.79
Upside: +7.53%
Doximity
Feb 10, 2026
Maintains: Neutral
Price Target: $45 → $34
Current: $25.52
Upside: +33.23%
Envista Holdings
Feb 10, 2026
Maintains: Neutral
Price Target: $24 → $27
Current: $24.30
Upside: +11.11%
Cardinal Health
Feb 6, 2026
Maintains: Outperform
Price Target: $222 → $235
Current: $188.60
Upside: +24.60%
McKesson
Feb 5, 2026
Maintains: Neutral
Price Target: $880 → $885
Current: $765.23
Upside: +15.65%
Align Technology
Jan 20, 2026
Maintains: Outperform
Price Target: $170 → $200
Current: $165.53
Upside: +20.82%
Jan 20, 2026
Upgrades: Outperform
Price Target: $85 → $100
Current: $72.29
Upside: +38.34%
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $40.19
Upside: +19.43%
Nov 6, 2025
Maintains: Outperform
Price Target: $340 → $380
Current: $264.11
Upside: +43.88%
Oct 30, 2025
Maintains: Outperform
Price Target: $48 → $50
Current: $21.07
Upside: +137.30%
Aug 29, 2025
Maintains: Outperform
Price Target: $295 → $325
Current: $165.90
Upside: +95.91%
Jul 25, 2025
Initiates: Neutral
Price Target: $10
Current: $7.04
Upside: +42.15%
Dec 4, 2024
Initiates: Outperform
Price Target: $126
Current: $83.65
Upside: +50.63%
Dec 4, 2024
Initiates: Outperform
Price Target: $5
Current: $5.20
Upside: -3.75%
Sep 21, 2023
Maintains: Equal-Weight
Price Target: $142
Current: $170.90
Upside: -16.91%
Aug 4, 2023
Maintains: Overweight
Price Target: $55
Current: $87.35
Upside: -37.03%
Aug 2, 2023
Maintains: Overweight
Price Target: $82 → $92
Current: $216.51
Upside: -57.51%
Apr 14, 2023
Maintains: Overweight
Price Target: $565
Current: $373.93
Upside: +51.10%
Mar 30, 2023
Maintains: Overweight
Price Target: $110 → $100
Current: $89.63
Upside: +11.58%
Oct 28, 2022
Maintains: Overweight
Price Target: $380 → $400
Current: $184.23
Upside: +117.12%
Jul 28, 2022
Reinstates: Overweight
Price Target: $107
Current: $54.72
Upside: +95.54%
Apr 18, 2022
Downgrades: Equal-Weight
Price Target: $22 → $17
Current: $40.98
Upside: -58.52%
Jun 11, 2021
Upgrades: Overweight
Price Target: $5 → $12
Current: $13.44
Upside: -10.68%
Nov 23, 2020
Upgrades: Overweight
Price Target: $96
Current: $107.34
Upside: -10.56%
Apr 30, 2020
Reiterates: Neutral
Price Target: $105 → $120
Current: $188.70
Upside: -36.41%
Apr 22, 2020
Maintains: Overweight
Price Target: $117 → $127
Current: $434.27
Upside: -70.76%
Dec 6, 2019
Maintains: Overweight
Price Target: $327 → $358
Current: $257.60
Upside: +38.98%